Összefoglaló. Az idült betegségek, köztük a gyulladásos bélbetegség kezelése összetett feladat, amely a megfelelő technikai feltételek mellett naprakész szaktudással és tapasztalattal rendelkező egészségügyi személyzet együttműködését igényli. Célunk a gyulladásos bélbetegség ellátásának célirányos összegzése volt. Kiemelten foglalkoztunk a korai diagnosztika és szakorvoshoz utalás kérdésével, a korszerű ellátáshoz szükséges, személyre szabott terápia és a célértékre történő kezelés, valamint a biológiai terápiás centrumba utalás szükségességével. Részleteztük továbbá a kompetens és felelősségteljes gondozás ellátószintjeit, és bemutattuk az ellátásban együttműködő multidiszciplináris csoport felépítését is. Az összefoglaló közleményhez a nemzetközi irodalmat és a hazai terápiás protokollokat tekintettük át. A krónikus betegségek gondozásában elengedhetetlen a társszakmák együttműködése. A betegség kezelésében fontos a folyamatosan változó ajánlások, protokollok ismerete és a kompetenciaszintek elfogadása a beteg megfelelő életminőségének elérése és a szövődmények csökkentése céljából. Orv Hetil. 2021; 162(33): 1311–1317.
Summary. The treatment of chronic diseases, including inflammatory bowel disease, is a complex task that requires the collaboration of health professionals with up-to-date expertise and experience under the appropriate technical conditions. Our aim was to systematically review the management of inflammatory bowel disease. We focused on the issue of early diagnosis and referral to a specialist, the need for personalized therapy and “treat-to-target” concept, and the appropriate timing of referral to a biological therapy center. The levels of competent and responsible care and the structure of a multidisciplinary team were also discussed. For the article, international and Hungarian therapeutic protocols and literature were reviewed. The collaboration of disciplines is essential in the management of chronic diseases. For disease management, it is critical to be up-to-date with changing recommendations, protocols, and to adopt competency levels to achieve a patient’s adequate quality of life and reduce disease complications. Orv Hetil. 2021; 162(33): 1311–1317.
Schoepfer A, Vavricka S. The ‘Red Flag Instrument’ for early detection of Crohn’s disease: is it ready for clinical practice? J Crohns Colitis 2015; 9: 597–598.
Danese S, Fiorino G, Mary JY. al. Development of Red Flags Index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative. J Crohns Colitis 2015; 9: 601–606.
Maaser C, Sturm A, Vavricka SR, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019; 13: 144–164.
Sands BE. Biomarkers of inflammation in inflammatory bowel disease. Gastroenterology 2015; 149: 1275–1285.e2.
Simon EG, Wardle R, Thi AA, et al. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease? A systematic review. Intest Res. 2019; 17: 160–170.
Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426–431.
Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National cooperative Crohn’s disease study. Gastroenterology 1976; 70: 439–444.
Irvine EJ. Usual therapy improves perianal Crohn’s disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol. 1995; 20: 27–32.
Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008; 14: 1660–1666.
Daperno M, D‘Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc. 2004; 60: 505–512.
Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013; 145: 987–995.
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 1625–1629.
Colombel JF, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology 2017; 152: 351–361.e5.
Torres J, Billioud V, Sachar DB, al. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012; 18: 1356–1363.
Nguyen VQ, Jiang D, Hoffman SN, al. Impact of diagnostic delay and associated factors on clinical outcomes in a U. S. inflammatory bowel disease cohort. Inflamm Bowel Dis. 2017; 23: 1825–1831.
Zaharie R, Tantau A, Zaharie F, al. Diagnostic delay in Romanian patients with inflammatory bowel disease: risk factors and impact on the disease course and need for surgery. J Crohns Colitis 2016; 10: 306–314.
InforMed. Biological therapy centers. [Biológiai terápiás centrumok.] Available from: www.informed.hu/ibdambulancia/centrumok/biologiai-terapias-centrumok-171049.html?fbclid=IwAR25gLNG6sXT78E3vFN0fA_so0_4x3VfCM8mAW5UyZhbYOfN_kRJb6atxkA; [accessed: February 3, 2021]. [Hungarian]
Decree No. 31/2010 (V. 13.) of the Ministry of Health on the regulation on financing procedures. [31/2010. (V. 13.) EüM rendelet a finanszírozási eljárásrendekről.] Available from: https://net.jogtar.hu/jogszabaly?docid=a1000031.eum [accessed: February 3, 2021]. [Hungarian]
Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015; 110: 1324–1338.
Kemp K, Dibley L, Chauhan U, et al. Second N-ECCO consensus statements on the European nursing roles in caring for patients with Crohn’s disease or ulcerative colitis. J Crohns Colitis 2018; 12: 760–776.
Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68(Suppl 3): s1–s106. [Erratum: Gut 2021; 70: 1.]
Erős A, Soós A, Hegyi P, et al. Spotlight on transition in patients with inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2020; 26: 331–346.
Otto C, Tárnok A, Erős A, et al. Planned transition of adolescent patients with inflammatory bowel disease results in higher remission rates. J Pediatr Nurs. 2019; 45: 62–66.
Magyar A. (ed.) Gastroenterology in general practice. [Gasztroenterológia a háziorvosi gyakorlatban.] Springmed Kiadó, Diósd, 2019. [Hungarian]
Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn’s disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012; 18: 2225–2231.
Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019; 25: 1896–1905.
D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008; 371: 660–667.